Artera
😁 We're delighted @arteraai.bsky.social are sponsoring From Ideas to Innovation.
🏥 Global leaders in precision medicine, leveraging multimodal intelligence to personalise cancer care.
🗣️ Speak to Artera's Director of Product Management at the event to hear more
prostatecanceruk.org/research/for...
Scientific Paper published in Oncogene, titled: Disruption of androgen receptor-cofactor interactions by the RNA-binding protein FUS/TLS alters androgen signalling in prostate cancer. Written by Brooke et al.
How does FUS regulate androgen receptor activity during #ProstateCancer progression?
Researchers @imperialsandc.bsky.social & @universityofessex.bsky.social, including Dr Greg Brooke, Dr Damien Leach & Prof Charlotte Bevan, share new findings in Oncogene.
Grab a ☕ & read: doi.org/10.1038/s413...
A person is sitting at a table, writing in a notebook. A laptop is open in front of them displaying a video conference with two participants. A cup of tea with a slice of lemon sits nearby. The environment appears calm and focused.
We’re teaming up with Movember to improve the sexual health & wellbeing of men with prostate cancer.
Sign up to our webinar and be among the first to hear about a new funding call!
📅 25 March
⏰ 6 - 7:15 pm
📍 Online on Teams
Find out more ➡️https://buff.ly/pP1w5b0
📢 Final week to apply for the @acmedsci.bsky.social Starter Grants for Clinical Lecturers, in partnership with @prostatecanceruk.bsky.social. Don't miss the 16:00 BST deadline on 26 February 2026!
More details 👉 acmedsci.ac.uk/starter-grants
#researchcareers #researchfunding #prostatecancer
Scientific paper published in BMJ Open, titled "Protocol for the PROSECCA study: a new approach for predicting radiotherapy outcome using artificial intelligence and electronic population-based healthcare data" written by Nailon et al.
Could AI predict outcomes and side-effects of radiotherapy in men with #prostatecancer?
Prostate Cancer UK funded Prof. Bill Nailon and Prof. Duncan McLaren @edinburgh-uni.bsky.social detail how they'll answer this question in BMJ Open.
Grab a ☕ and read: bmjopen.bmj.com/content/16/2...
Picture of Professor Clare Verrill
The February edition of Research News is here! Discover more about:
🔬 An exciting research project.
💸 Our new funding committee chairs.
💙 Our updated Research Impact webpages.
🏆 Researcher achievements.
💰 Funding opportunities.
📖 Read it here: buff.ly/azyVGlK
A person sits at a table with an open laptop displaying a video call and a document. They write notes in a notebook. A cup with a hot beverage is nearby.
💻 Prostate Cancer UK Online Learning
Free courses, webinars & resources to build your knowledge and earn self-accredited CPD.
Flexible, practical learning for busy health professionals.
➡️ buff.ly/gm2hkMG
#ProstateCancer #CPD
📢 We’re supporting @acmedsci.bsky.social to provide up to £40K over 2 years to Clinical Lecturers looking to develop and strengthen their research careers.
Funding deadline is 26 February 2026.
Visit AMS website for more info 👉 acmedsci.ac.uk/starter-grants
#CareerDevelopment #ResearchFunding
Scientific Paper published in European Radiology, titled: Semi-supervised learning in prostate MRI tumor detection approaches fully supervised performance on external validation. Written by Pooch et al.
Can AI learn to detect aggressive #ProstateCancer on MRI with limited expert input?
A team, including Prostate Cancer UK–funded Profs. Hashim Ahmed & Mark Emberton, publish findings in @europeanradiology.bsky.social powered by data from our funded research.
Grab a ☕ & read: doi.org/10.1007/s003...
📢 Do you know any rising stars⭐ in prostate cancer research? 🔬
Our Career Acceleration Fellowships offer up to £350k to help early career researchers pursue their own research goals and become future leaders in the field.
Share with your team today!
Picture of Professor Jonathan Coulter with a quote: Around 20-30% of men diagnosed with intermediate to high-risk localised cancers go onto develop recurrent disease. This is a statistic we are confident we can improve.
Professor Jonathan Coulter @qubelfastofficial.bsky.social leads a research team developing innovative cancer therapeutics.
Since 2021, we’ve supported his team in creating an implant that releases gold nanoparticles that sensitise #ProstateCancer to radiotherapy.
📙 Read more: buff.ly/vteN8gz
A person in a kitchen is watching a video on a tablet placed on a countertop, holding a yellow mug. The kitchen has green cabinets, wooden shelves, and various kitchen items.
💻 Join our free online Specialists Conference on 25–26 March for the latest updates in prostate cancer care.
Busy on the day? No worries — we’ll send you the recordings.
➡️ More details here: bit.ly/3EaVj3i
#prostatecancer #professionaldevelopment #secondarycare
[10/10] Professor Val Macaulay sadly passed away before the publication of this research article.
Professor Ian Mills, who carried this work through to completion, and team warmly dedicated the paper to Val.
Val will be a greatly missed member of the Prostate Cancer UK research community.
[9/10] 🧵 If you want to learn more about Professor Val Macaulay’s important research, including her wider WINGMEN trial, you can read our research impact page about her work: prostatecanceruk.org/research/res...
05.02.2026 14:02 — 👍 0 🔁 0 💬 1 📌 0
[8/10] 🧵 Together, these key findings demonstrate how IGF-1 enables prostate cancer cells to evade the immune system.
These findings suggest that blocking IGF-1 could help to increase the effectiveness of future immune therapies in men with prostate cancer.
[7/10] 🧵 The paper’s second key finding was that IGF-1 upregulates the expression of programmed death-ligand 1 (PD-L1).
PD-L1 is expressed by healthy cells to prevent autoimmune reactions. Cancer cells expressing increased levels of PD-L1 are less likely to be targeted by CD8+ T-cells.
[6/10] 🧵 The paper’s first key finding was that IGF-1 reduces the expression of genes that encode antigen presentation regulatory proteins.
Reduced antigen presentation enables the cancer cells to remain undetected by CD8+ T-cells, promoting the cancer’s survival.
[5/10] 🧵 IGF-1 is known to promote prostate cancer cell growth, but Professor Macaulay wanted to find out if IGF-1 also helped the cancer cell evade the immune system.
🧬 So, the team investigated the effect that IGF-1 has on known immune suppression genes.
[4/10] 🧵 To find out more about how these mechanisms of immune therapy resistance are regulated, we funded Professor Valentine Macaulay to investigate insulin-like growth factor 1 (IGF-1) and its effect on prostate cancer cells.
👩🔬 This work is part of Valentine’s wider WINGMEN trial:
[3/10] 🧵 Mechanisms like reduced antigen presentation and T-cell signalling inhibition help cancer cells evade the immune system.
❓️ But how these mechanisms are regulated is less understood. Figuring this out could help immune therapies to be more effective against prostate cancer.
[2/10] 🧵 Immune therapies are largely ineffective against #ProstateCancer.
Prostate cancer cells often evade the adaptive immune system, nullifying the positive effect that immune therapy drugs could have.
So, how do cancer cells evade the immune system?
[1/10] 🧵 How does IGF-1 help cancer cells evade the immune system?
Let's unpack the results observed in a recently published article in Scientific Reports by a team including Prostate Cancer UK funded Professor Valentine Macaulay and Professor Ian Mills.
bsky.app/profile/did:...
Could molecular profiling of circulating tumour cells (CTCs) improve clinical management of #ProstateCancer?
Progress on this topic is reviewed by a team including Prostate Cancer UK funded Professor Yong-Jie Lu @qmbci.bsky.social in @natrevurol.nature.com.
Grab a ☕ and read: bit.ly/46ti2CJ
📢 Seize the opportunity to boost your future research career as a Clinical Lecturer!
Thanks to @prostatecanceruk.bsky.social partnership with @acmedsci.bsky.social, you can apply for a Starter Grant by 26 February 2026.
Learn more 👉 acmedsci.ac.uk/starter-grants
#researchfunding #prostatecancer
⏰ 12 days to go: CRSG proposal deadline
💡 Got a new trial idea to improve outcomes for men with prostate cancer?
Get early guidance and feedback from the CRSG.
🗓 Deadline: 4pm, Fri 13 Feb
Scientific Review Paper published in Expert Opinion on Therapeutic Targets, titled: Blocking glycan production by targeting GALNT7 for prostate cancer therapy. Written by Peng et al.
Could GALNT7 be a promising therapeutic target for #ProstateCancer?
A team led by Dr Jennifer Munkley @newcastleuni.bsky.social explores the enzyme's role & emerging strategies to inhibit its activity, writing in Expert Opinion on Therapeutic Targets.
Grab a ☕ & read: doi.org/10.1080/1472...
📢 Are you a Clinical Lecturer looking to develop and strengthen your research career?
The @acmedsci.bsky.social Starter Grants funding call is now OPEN.
Deadline: 26 February 2026.
More details 👉 acmedsci.ac.uk/starter-grants
#CareerDevelopment #ResearchFunding
Image of researcher working in the lab, with a graphic in the top right corner saying 'Research News, January 2026'.
The January edition of Research News is here! Find out about:
🎯 How we measure the success of our funded research
🥼 UK Prostate Cancer Clinical Research Strategy Group
🧪 Research funding opportunities
📖 External workshops
Read here: buff.ly/l43rtlW
Coming soon! 📢
Applications for our Career Acceleration Fellowships open in March. We’re offering up to £350K over 3-4 years to support early career prostate cancer researchers to advance their career and build collaborations.
🚨Find out more here: buff.ly/E2yRcy8
Huge congratulations to @mitosrus.bsky.social and the team @cruk-si.bsky.social for this well deserved recognition 👏
26.01.2026 09:09 — 👍 4 🔁 1 💬 0 📌 0